Literature DB >> 6799544

Binding properties and subclass distribution of anti-acetylcholine receptor antibodies in myasthenia gravis.

A K Lefvert, S Cuénoud, B W Fulpius.   

Abstract

Acetylcholine receptor antibodies were studied in the serum of 21 myasthenic patients. In 18 cases antibodies directed against sites other than the toxin binding were present whereas in 10 cases only there was a measurable inhibition of the ligand binding site. These 10 sera were from the 6 patients in stage IIB, III and IV and from 4 of the 12 patients in stage IIA. Antibodies against both non-toxin and ligand binding sites were measured in IgG subclasses. Most of the antibodies of the first type belonged to either subclass 1 or 3. They were, however, never absent from subclasses 2 and 4. Antibodies of the second type were not found in subclasses 2 and 4 except in one case. In 3 cases they were present exclusively in subclass 3. In 3 patients there was no correlation between the subclass distribution of the antibodies for the different binding sites.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6799544     DOI: 10.1016/0165-5728(81)90015-1

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  13 in total

Review 1.  Immunopathologic events at the endplate in myasthenia gravis.

Authors:  T Ashizawa; S H Appel
Journal:  Springer Semin Immunopathol       Date:  1985

2.  Relation of HLA-DRB1 to IgG4 autoantibody and cytokine production in muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG).

Authors:  M Çebi; H Durmuş; V Yılmaz; S P Yentür; F Aysal; P Oflazer; Y Parman; F Deymeer; G Saruhan-Direskeneli
Journal:  Clin Exp Immunol       Date:  2019-04-12       Impact factor: 4.330

Review 3.  B cells in the pathophysiology of myasthenia gravis.

Authors:  John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2017-09-30       Impact factor: 3.217

Review 4.  IgG4 and the immune system.

Authors:  L Perelmutter
Journal:  Clin Rev Allergy       Date:  1983-06

5.  Elevated N-Linked Glycosylation of IgG V Regions in Myasthenia Gravis Disease Subtypes.

Authors:  Caleigh Mandel-Brehm; Miriam L Fichtner; Ruoyi Jiang; Valerie J Winton; Sara E Vazquez; Minh C Pham; Kenneth B Hoehn; Neil L Kelleher; Richard J Nowak; Steven H Kleinstein; Michael R Wilson; Joseph L DeRisi; Kevin C O'Connor
Journal:  J Immunol       Date:  2021-09-20       Impact factor: 5.426

6.  The Beneficial Clinical Effects of Teriflunomide in Experimental Autoimmune Myasthenia Gravis and the Investigation of the Possible Immunological Mechanisms.

Authors:  Emel Koseoglu; Neslihan Sungur; Sabahattin Muhtaroglu; Gokmen Zararsiz; Ahmet Eken
Journal:  Cell Mol Neurobiol       Date:  2022-10-11       Impact factor: 4.231

7.  Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3.

Authors:  A Rødgaard; F C Nielsen; R Djurup; F Somnier; S Gammeltoft
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

8.  Protective effect of myasthenic immunoglobulins against the lethal toxicity of alpha bungarotoxin.

Authors:  B Vernet-der Garabedian; J F Bach; E Morel
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

9.  Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis.

Authors:  Ruoyi Jiang; Kenneth B Hoehn; Casey S Lee; Minh C Pham; Robert J Homer; Frank C Detterbeck; Inmaculada Aban; Leslie Jacobson; Angela Vincent; Richard J Nowak; Henry J Kaminski; Steven H Kleinstein; Kevin C O'Connor
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-16       Impact factor: 11.205

Review 10.  Short- and Long-Lived Autoantibody-Secreting Cells in Autoimmune Neurological Disorders.

Authors:  C Zografou; A G Vakrakou; P Stathopoulos
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.